In cancer patients, dendritic cells (DCs) in tumor-draining lymph nodes can present antigens
to naive T cells in ways that break immunological tolerance. The clonally expanded progeny …

In the tumour microenvironment (TME), immunogenic cell death (ICD) plays a major role in
stimulating the dysfunctional antitumour immune system. Chronic exposure of damage …

Cancer immunotherapies that train or stimulate the inherent immunological systems to
recognize, attack, and eradicate tumor cells with minimal damage to healthy cells have …

Innate immunity is maintained in part by antigen presenting cells (APCs) including dendritic
cells, macrophages, and B cells. APCs interact with T cells to link innate and adaptive …

In recent years, conventional treatments including surgery, chemotherapy and radiotherapy
have been the main approaches in tumour therapy. Cancer immunotherapy is a new …

Immunogenic cell death (ICD) and tumour-infiltrating T lymphocytes are severely weakened
by elevated reactive oxygen species (ROS) in the tumour microenvironment. It is therefore of …

In the past few years, cancer immunotherapy has emerged as a safe and effective
alternative for treatment of cancers that do not respond to classical treatments, including …

The immunogenicity of cancer cells is an emerging determinant of anti‐cancer
immunotherapy. Beyond developing immunostimulatory regimens like dendritic cell‐based …

Photodynamic therapy (PDT) is considered a pioneering and effective modality for cancer
treatment, but it is still facing challenges of hypoxic tumors. Recently, Type I PDT, as an …

In recent years, photothermal therapy (PTT) particularly nanomaterial-based PTT is a
promising therapeutic modality and technique for cancer tumor ablation. In addition to killing …